Sign up Australia
Proactive Investors - Run By Investors For Investors

OBJ Limited to reveal licensing details

The halt will remain in place until Monday 24th April 2017.
OBJ Limited to reveal licensing details
The company is focused on drug delivery technology

OBJ Limited (ASX:OBJ) has been granted a trading halt by the ASX, pending details in relation to the licensing of a second technology.

The halt will remain in place until the opening of trade on Monday 24th April 2017, or earlier if an announcement is made to the market.

View full OBJ profile View Profile

OBJ Ltd Timeline

Newswire
January 25 2016
Newswire
December 02 2014

Related Articles

Lab technician
August 07 2017
Avacta said it has developed multiple PD-L1 inhibitors, which are designed to use the body's own immune system to battle cancer
picture of drug research
01:08
With US licensee driving the Phase 1 trials of Sareum's lead candidate, SRA737, the focus moves to TYK2, a compound that is targeting psoriasis, rheumatoid arthritis, and other autoimmune disorders
newspaper with word cancer magnified
July 11 2017
"In our view, the potential for SCIB1 [Scancell's skin cancer treatment], as already demonstrated by the survival data, is remarkable," said one broker recently

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use